its relevance to retatrutide specifically is not yet established A history of pancreatitis or significant gastrointestinal disease Gallbladder disease , including a history of gallstones or cholecystitis Diabetes mellitus , particularly if managed with insulin or sulphonylureas, due to hypoglycaemia risk Cardiovascular disease , including arrhythmias or recent cardiac events Renal or hepatic impairment , which may affect tolerability and increase the risk of dehydration-related complications Pregnancy or breastfeeding no safety data exist for retatrutide in these groups Use of oral medicines where absorption may be affected by delayed gastric emptying , such as levothyroxine or combined oral contraceptives Seek urgent medical attention if you experience severe or persistent nausea or vomiting, persistent abdominal pain (which may indicate pancreatitis or gallbladder disease), signs of an allergic reaction (rash, swelling, difficulty breathing), chest pain, palpitations, or signs of dehydration

The agency advised Canadians to obtain prescription medications only from licensed pharmacies with proper authorization, as many of these products may be contaminated, mislabeled, or dangerous
3G and EV3G, UBQLN2 immunoreactivity was clearly observed in LBs in the substantia nigra of four sporadic PD patients, whereas background signal was barely detectable in the control IgG
Lotte S, Sofie P, Cathrine O, et al